Abivax stock declines but retains nearly 38% gain over one year
The Paris-based biotech is losing ground this Tuesday in a declining market, while short seller positions on the stock have increased by one percentage point over a month. First-half 2026 results are expected next week, on September 21.
A decline below the three moving averages in a context of market pressure
Abivax is down 2.26% to €97.40 during the session, while the SBF 120 is also falling 0.75%. The stock is trading below its 20-day moving average at €100.20 (a gap of 2.79%), below its 200-day moving average at €102.96, and significantly below its 50-day moving average at €108.70. This positioning below all of its moving averages reflects sustained pressure over several weeks, which today's market context does nothing to alleviate. In the background, the Federal Reserve is widely expected to raise rates on Wednesday, in an environment where 10-year Treasury yields have exceeded 5% and the VIX has risen more than 12% during the session to 17.84.
This tightening of financial conditions and rising volatility are broadly weighing on risk assets, among which biotech stocks remain particularly exposed. The RSI at 41 remains in neutral territory, without signaling marked selling exhaustion for the moment. The support level at €96.65 is the next threshold to monitor: it has already been tested several times this summer and represents the last line of technical defense before new lows.
Short positions rising as first-half results approach
According to recorded declarations, cumulative net short positions on Abivax reach 5.90% of share capital, distributed among five funds, up 0.86 percentage points over thirty days. This relatively high level indicates that a significant fraction of institutional investors is positioned against the stock or hedging an existing exposure. However, the recent increase in shorts does not indicate the precise motivations of these funds (hedging, arbitrage, directional bet) and should be read as a signal for vigilance rather than as a verdict on the stock's value.
Over the longer term, Abivax maintains a performance of 37.77% over one year, despite a decline of 5.16% over one month and a limited fall of 0.56% over the week. The publication of first-half 2026 results, scheduled for September 21, will constitute the next factual point of information for the market on the company's operational trajectory.
